Curie Cancer partner of the 1st Cell Therapy Innovation 360° congress

Carnot Curie Cancer, partner of the 1st Cell Therapy Innovation 360° (CTI 360°) congress.

The development of genetically engineered T-cells constitutes a powerful new class of therapeutic agents that offers a new hope for cancer patients.

CAR T-cells in acute leukemia and diffuse large B-cell lymphoma were recently approved by the FDA and EMA and more than one hundred clinical trials are ongoing. This is definitely an emerging therapeutic breakthrough.

The aim of the Cell Therapy Innovation 360° (CTI 360°) congress is to become a reference in cell-therapy perspectives and issues in Onco-hematology issues. CTI 360° will bring together all the key French and European players in the field on May 21 and 22, 2019, in Lyon, France.

During these two days, the meeting will adopt a 360° vision of all hot topics in order to:

• Gain insight into mechanisms of action
• Understand the specificities of cellular therapies
• Put into perspective clinical results and current developments
• Understand emerging toxicities
• Share new algorithms
• Define challenges and new models to market access
• Revise the organization of patient management, especially patient journey: on a local, regional, national and international level
• Share experience from the United States and from European countries where cellular therapies are already available

We very much hope you can join us and we look forward to welcoming you in May 2019 for what promises to be a therapeutic revolution, a clinical reality and a new breakthrough for any actors fighting against cancer, but more specifically for patients."

Yours sincerly,

Professors Gilles SALLES & Jean-Yves BLAY